Induced activation in dendritic cell

Details Induced activation in dendritic cell Induced activation in dendritic cell

2008-07-29

2008-07-29

Li, Q. Janice (Department: 1633)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

C424S093100, C424S093200, C536S023100, C536S023400, C514S04400A

Reexamination Certificate

active

07404950

ABSTRACT:
The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

REFERENCES:
patent: 5741899 (1998-04-01), Capon et al.
patent: 5830462 (1998-11-01), Crabtree et al.
patent: 5834266 (1998-11-01), Crabtree et al.
patent: 5869337 (1999-02-01), Crabtree et al.
patent: 5871753 (1999-02-01), Crabtree et al.
patent: 5994313 (1999-11-01), Crabtree et al.
patent: 6011018 (2000-01-01), Crabtree et al.
patent: 6043082 (2000-03-01), Crabtree et al.
patent: 6046047 (2000-04-01), Crabtree et al.
patent: 6046158 (2000-04-01), Ariizumi et al.
patent: 6054436 (2000-04-01), Crabtree et al.
patent: 6497876 (2002-12-01), Maraskovsky et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6670186 (2003-12-01), Nair et al.
patent: 2003/0082163 (2003-05-01), Shu
patent: 2003/0091593 (2003-05-01), Bachmann et al.
patent: 2003/0108527 (2003-06-01), Seya et al.
patent: 2003/0153518 (2003-08-01), Foxwell et al.
patent: 2003/0206917 (2003-11-01), Tykocinski et al.
patent: 2003/0232055 (2003-12-01), Medzhitov
patent: 2004/0019195 (2004-01-01), Scholm et al.
patent: WO-9612796 (1996-05-01), None
patent: WO-0183551 (2001-11-01), None
patent: WO 0236769 (2002-05-01), None
Jacquot et al, J Immunol 1997; 159: 2652-7.
Tong et al, Cancer Gene Therapy 2003;10:1-13.
Bowie et al, Science Mar. 1990; 247:1306-10.
Rudinger, Peptide Hormones 1976; June;pp. 1-7.
Deonarain, 1998, Expert Opin. Ther. Pat., vol. 8, pp. 53-69.
Kopytek et al, Chem & Biol 2000;7:313-21.
Amara et al, PNAS 1997:94:10618-23.
de Gruijl et al, “Prolonged Maturation and Enhanced Transduction of Dendritic Cells Migrated from Human Skin Explants After In Situ Delivery of CD40-Targeted Adenoviral Vectors,” The Journal of Immunology vol. 169, 2002, pp. 5322-5331.
Rivera, V.M., “Controlling Gene Expression Using Synthetic Ligands,” Methods: A companion to Methods in Enzymology vol. 14, 1998, pp. 421-429.
Tong et al, “Prospects for CD40-directed Experimental Therapy of Human Cancer,” Cancer Gene Therapy vol. 10, 2003, pp. 1-13.
Richard et al, “Expansion of Genetically modified Primary Human Hemopoietic cells Using Chemical Inducers of Dimerization,” Blood vol. 95, 2000, pp. 430-436.
Chiodoni et al, “Dendritic Cells Infiltrating Tumors Cotransduced with Granulocyte/Macrophage Colony-Stimulating factor (GM-CSF) and CD40 Ligand Genes Take Up and Present Endo genous Tumor-Associated Antigens, and Prime Naive Mice for a Cytotoxic T Lymphocyte Response,” J. Exp. Med. vol. 190, No. 1, Jul. 5, 1999, pp. 125-133.
Sato et al, “Combination of monocyte-derived dendritic cells and activated T cells which express CD40 ligand: a new approach to cancer immunotherapy,” Cancer Immunol Immunther vol. 53 No. 1, Jan. 2004, pp. 53-61.
Kempf et al, “Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles,” J Drug Target vol. 11 No. 1, Jan. 2003, pp. 11-18.
Melief et al, “Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes,” Immunol Rev. vol. 188, Oct. 2002, pp. 177-182.
Adam et al, “Cross-linking of the p55 Tumor Necrosis Factor Receptor Cytoplasmic Domain by a Dimeric Ligand Induces nuclear Factor-kB and Mediates Cell Death,” The Journal of Biological Chemistry vol. 270, No. 29, Jul. 21, 1995, pp. 17482-17487.
Steinman, R.a.P., M. Journal of Clinical Investigation vol. 109, 2002, pp. 1519-1526.
Goodwin, J.S., “Immunomodulation by eicosanoids and anti-inflammatory drugs,” Curr Opin Immunol, 1989, vol. 2, pp. 264-268.
Hanks B.A., et al., “Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo” Nature Medicine, vol. 11, No. 2, 2005 pp. 130-137.
Hauer et al., “TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2 5-mediated activation of the noncanonical NF- B pathway by TRAF-binding TNFRs,” PNAS, vol. 102, No. 8, Feb. 22, 2005, pp. 2874-2879.
Kadowaki N., et al., “Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens,” J Exp Med., 2001, vol. 194, pp. 863-869.
Kalinski P., et al., “Prostaglandin E2 is a selective inducer of human interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer,” Blood, 2001 Bol. 97, pp. 3466-3469.
Lapointe R., et al., “Human dendritic cells require multiple activation signals for the efficient generation of tumor antigen-specific T lymphocytes,” Eur J Immunol., 2000, vol. 30, pp. 3291-3298.
Luft T., et al., “Functionally distinct dendritic cells (DC) populations induced by physiologic stimuli: prostoglandin-producing E(2) regulates the migratory capacity of specific DC subsets,” Blood, 2002 vol. 100, pp. 1362-1372.
Napolitani et al., “Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendrinic cells,” Nat Immunol. Aug. 2005; vol. 6, No. 8, pp. 769-776.
Rescigno M., et al., “Dendritic cell survival and maturation are regulated by different signaling pathways,” J Exp Med., 1998, vol. 188, pp. 2175-2180.
Scandella E., et al., “Prostaglandin E2 is a key factor dof CCR7 surface expression and migration of monocyte-derived dendritic cells,” Blood, 2002, vol. 100 pp. 1354-1361.
Spencer D.M., et al., “Controlling signal transduction with synthetic ligands,” Science, Nov. 12, 1993, vol. 262 No. 5136, pp. 1019-1024.
Tai et al., “Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications,” Cancer Research, Apr. 15, 2004, vol. 64, pp. 2846-2852.
Tone M., et al., “Regulation of CD40 function by its isoforms generated through alternative splicing,” PNAS, Feb. 13, 2001, vol. 98, No. 4, pp. 1751-1756.
van der Pouw Krann T.C., et al., “Prostoglandin E2 is a potent inhibitor of human interleukin12 production,” J Exp Med., 1995, vol. 181, pp. 775-779.
Belshaw et al. (Sep. 1996). “Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization.” Chemistry & Biology. 3(9): pp. 731-738.
Spencer et al. (1996). “Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization.” Current Biology. 6(7): pp. 839-847.

Affiliated with

Also associated with

Rating

Induced activation in dendritic cell does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Induced activation in dendritic cell, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Induced activation in dendritic cell will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2809602